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Abstract
Background: Idiopathic interstitial pneumonias (IIPs) are a group of heterogeneous, somewhat unpredictable
diseases characterized by progressive scarring of the interstitium. Since lung function is a key determinant of
survival, we reasoned that the transcriptional profile in IIP lung tissue would be associated with measures of lung
function, and could enhance prognostic approaches to IIPs.
Results: Using gene expression profiling of 167 lung tissue specimens with IIP diagnosis and 50 control lungs, we
identified genes whose expression is associated with changes in lung function (% predicted FVC and % predicted
DLCO) modeled as categorical (severe vs mild disease) or continuous variables while adjusting for smoking status and
IIP subtype; false discovery rate (FDR) approach was used to correct for multiple comparisons. This analysis identified 58
transcripts that are associated with mild vs severe disease (categorical analysis), including those with established role in
fibrosis (ADAMTS4, ADAMTS9, AGER, HIF-1α, SERPINA3, SERPINE2, and SELE) as well as novel IIP candidate genes such as
rhotekin 2 (RTKN2) and peptidase inhibitor 15 (PI15). Protein-protein interactome analysis of 553 genes whose
expression is significantly associated with lung function when modeled as continuous variables demonstrates
that more severe presentation of IIPs is characterized by an increase in cell cycle progression and apoptosis,
increased hypoxia, and dampened innate immune response. Our findings were validated in an independent cohort of
131 IIPs and 40 controls at the mRNA level and for one gene (RTKN2) at the protein level by immunohistochemistry in
a subset of samples.
Conclusions: We identified commonalities and differences in gene expression among different subtypes of IIPs. Disease
progression, as characterized by lower measures of FVC and DLCO, results in marked changes in expression of novel and
established genes and pathways involved in IIPs. These genes and pathways represent strong candidates for biomarker
studies and potential therapeutic targets for IIP severity.
Background
There is substantial clinical heterogeneity in the clinical,
radiologic, and histopathologic features within each sub-
type of idiopathic interstitial pneumonias (IIPs). For in-
stance, all forms of IIP have a somewhat unpredictable
prognosis and many but not all patients can progress to
end stage lung disease [1–3]. While subtypes of IIPs differ
in clinical, radiographic, and histopathologic presentation
[1–3], the type of IIP often cannot be determined and
many of the subtypes of IIP have overlapping clinical and
laboratory features indicating that the current definitions
remain too broad.
Idiopathic pulmonary fibrosis (IPF), by far the most
common form of IIP, is histopathologically defined by the
presence of the prototypical form of pulmonary fibrosis,
usual interstitial pneumonia (UIP), a fibrosing interstitial
pneumonia characterized by a pattern of heterogeneous,
subpleural regions of fibrotic, and remodeled lung that
often results in death within 2–3 years of diagnosis [4].
Other IIPs, such as respiratory bronchiolitis-associated
interstitial lung disease (RB-ILD), are more cellular, occur
earlier in life, and have a considerably lower mortality [5].
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By contrast, idiopathic nonspecific interstitial pneumo-
nia (iNSIP), a pattern of IIP that is more likely a syn-
drome than a disease, is most commonly characterized
by interstitial fibrosis but in a more uniform pattern
than UIP, and carries a better prognosis than IPF/UIP
[6, 7]. These differences within the subtype and overlaps
among subtypes create a distinct challenge to achieve an
accurate diagnosis for an individual patient with this po-
tentially life-threatening diagnosis.
The molecular mechanisms that account for the extreme
heterogeneity in clinical presentation, radiologic patterns,
histopathologic variation, and disease progression are largely
unknown. We hypothesize that biological heterogeneity in
IIPs will be reflected by gene expression patterns in lung tis-
sue from patients with IIP, and gene expression patterns will
change as a function of disease activity, progression, and se-
verity. To test this hypothesis, we measured gene expression
in lung tissue of patients with IIP, and correlated gene ex-
pression patterns with diffusing capacity of the lung for car-
bon monoxide (DLCO) and forced vital capacity (FVC).
Results
Demographic characteristics of the Lung Tissue Research
Consortium (LTRC) cohort
Table 1 summarizes demographic and clinical characteris-
tics of the LTRC IIPs cohort and by subtypes of IIPs that
include at least 10 individuals. Included in the table is the
portion of the non-diseased control cohort used together
with the LTRC cohort. Overall, the IIPs cohort is older than
the controls. Within the IIP cohort, individuals within IPF/
UIP group are the oldest followed by iNSIP, uncharacter-
ized fibrosis, and RB-ILD. There are no significant differ-
ences across IIP subtypes in gender or racial distribution.
Comparison of smoking histories reveals that approxi-
mately half of the individuals with IIP are former smokers,
as compared to controls that are almost 50 % current
smokers. Subjects with IPF/UIP and RB-ILD diagnosis re-
ported higher pack-years compared to subjects with iNSIP,
uncharacterized fibrosis, and controls; however, there is
variability within each group and therefore there are no sta-
tistically significant differences among groups. We also
compared St. George’s score, an indicator of overall lung
health [8] in subtypes of IIP (no data available for controls)
and did not find significant differences among groups. Fi-
nally, variables associated with lung function, % predicted
pre-bronchodilator FVC and DLCO reveal better lung func-
tion in the RB-ILD group compared to other IIPs.
Identification of genes associated with the IIPs clinical
subtype
To establish whether there are significant differences in
expression in clinical subtypes of IIP, we first identified
molecular profiles associated with clinically defined sub-
types of IIP. For this initial analysis, we used an ANCOVA
model that incorporates clinical subtype with at least 10
individuals per group (including controls), age, gender and
smoking status as factors. Venn diagrams in Additional file
1: Figure S1 illustrate overlap of differentially expressed
mRNAs amongst IIP categories versus controls using the
5 % FDR criterion alone or combined 5 % FDR and 2-fold
Table 1 Subject demographics and clinical characteristics of the derivation (LTRC) cohort by IIP subcategory




Number 50 167 119 17 13 11
Age - mean (std dev) 47.5 (16.4) 60.9 (10.2) 62.6 (8.7) 57.2 (12.2) 56.7 (16.4) 52.2 (10.9) <0.0001* 0.0016***
Gender – % male 54 61 65 53 62 36 0.41** 0.27**
Race - % Caucasian 82 87 94 82 85 82 0.067** 0.18**
Smoker – <0.0001** 0.12**
Current 21 (42 %) 3 (3 %) 0 (0 %) 1 (6 %) 0 (0 %) 1 (9 %)
Former 7 (14 %) 96 (55 %) 70 (59 %) 11 (65 %) 6 (46 %) 6 (55 %)
Never 20 (40 %) 58 (35 %) 41 (34 %) 4 (24 %) 7 (54 %) 4 (36 %)
Unknown 2 (4 %) 10 (7 %) 8 (7 %) 1 (6 %) 0 (0 %) 0 (0 %)
Pack years - mean (std dev)b 22.1 (19.5) 58.6 (103) 69.9 (115) 20.5 (23.8) 21.8 (14.1) 53.3 (30.8) 0.080* 0.37***
St George’s score - mean (std dev) NA 48.3 (21.0) 46.6 (22.2) 50.9 (16.6) 54.5 (20.6) 37.8 (17.0) NA 0.24***
Pre-BD FVC, %predicted - mean (std dev) NA 63.1 (19.1) 61.3 (16.8) 69.9 (22.2) 59.7 (27.6) 85.7 (13.1) NA 0.0005***
DLCO, %predicted - mean (std dev) NA 48.4 (21.9) 45.9 (20.3) 58.7 (22.1) 48.7 (16.6) 77.1 (21.3) NA <0.0001***
aIIP = idiopathic interstitial pneumonia, IPF = idiopathic pulmonary fibrosis, UIP = usual interstitial pneumonia, iNSIP = idiopathic nonspecific interstitial pneumonia,
UF = uncharacterized fibrosis, RB-ILD = respiratory bronchiolitis associated interstitial lung disease. Data not reported individually for cryptogenic organizing pneumonia
(COP) (n = 3) and desquamative interstitial pneumonia (DIP) (n = 4) categories
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change criteria. While the statistical interpretation of
intersection-union testing among these groups is com-
promised by differences in the power of individual
contrasts and by the common comparator group, a
large proportion of the differentially expressed mRNA
transcripts exhibit differences between control lung
and two or more of the IIP subgroups. However, we
also observed genes unique to each IIP subtype, espe-
cially in the IPF/UIP group which has the most differen-
tially expressed transcripts overall as well as the most
unique transcripts. This result is likely a combination of
IPF/UIP being the largest group of IIPs examined in our
study and the fact that IPF/UIP has the most remodeled
lung of all IIPs. Examination of 29 genes in common to all
IIPs using the 5 % FDR and 2 fold change criteria reveals
genes involved in inflammation (IL1RL1, IL1R2, IL18R1,
IL8RAP), extracellular matrix (ITGA10, FCN3), Wnt sig-
naling (SFRP2), coagulation (alpha-1 antichymotrypsin or
SERPINA3) and host defense (DEFA3) (Additional file 1:
Table S1). Interestingly, defensin DEFA3 is one of the genes
we identified as differentially expressed in peripheral blood
of severe vs mild IPF/UIP categorized by differences in the
DLCO [9]. We used the high degree of overlap among IIPs
and biological relevance of genes identified in common to
all IIPs as a rationale for inclusion of all IIP subtypes in the
analysis of lung function variables as opposed to focusing
only on IPF/UIP; however, we adjust for IIP subtype in all
further analyses.
Identification of genes associated with DLCO
We next sought to identify genes whose expression is
associated with the DLCO measurement. For this analysis,
we used an ANOVA model that incorporates categories of
disease based on predicted DLCO (see below), IIP subtype
and smoking status, or an ANCOVA model that incorpo-
rates the % predicted DLCO measurement, IIP subtype
and smoking status as factors. Although no significant dif-
ference in smoking status exist among IIPs due to high
variability in each IIP subtype, differences in smoking
histories in these individuals may influence gene expres-
sion and we therefore included them in the model. We
did not include age and gender because they are
accounted for in the calculation of % predicted lung
function variables. By categorical analysis, 91 unique
transcripts differentiate mild disease (DLCO ≥65 %; n = 33)
from severe disease (DLCO ≤35 %; n = 40) at 5 % FDR
(Additional file 1: Table S2). When DLCO is treated as a
continuous variable (135 subjects with DLCO measure-
ment available), 706 genes correlate with changes in % pre-
dicted DLCO at 5 % FDR (Additional file 1: Table S3). Six
hundred fourteen genes not identified in the categorical
analysis were found to be associated with changes in DLCO
in the continuous analysis.
Identification of genes associated with FVC
We also identified gene expression changes associated
with the FVC measurement, in an analogous manner to
the analysis of DLCO. By categorical analysis, 681 genes
differentiate mild disease (FVC ≥75 %; n = 50) from severe
disease (FVC ≤40 %; n = 40) when categorized by % pre-
dicted FVC at 5 % FDR (Additional file 1: Table S4). Two
thousand four hundred sixty seven genes correlate with
changes in % predicted FVC in 164 subjects with available
FVC data at 5 % FDR (Additional file 1: Table S5) with
1794 of these transcripts not overlapping with categorical
analysis.
Transcriptional changes in common to decline in DLCO
and FVC
To focus on genes that are the most likely to be involved
in the pathogenesis of IIP, we identified differentially
expressed transcripts in common to lower measures of
DLCO and FVC. We first intersected 91 transcripts iden-
tified as significant in the categorical analysis of disease
severity based on DLCO and 681 from the analogous
analysis of FVC. Fifty eight transcripts that are in com-
mon to the two analyses are listed in Table 2. While a
number of these transcripts, including ADAMTS family
members (ADAMTS4, ADAMTS9) [10], AGER [11],
HIF-1α [12, 13], serpin family members (SERPINA3,
SERPINE2) [14], and selectin E (SELE) [15] have an
established role in lung fibrosis, expression of novel IIP
candidate genes such as rhotekin 2 (RTKN2) and peptid-
ase inhibitor 15 (PI15) is also significantly altered in se-
vere compared to mild disease. Dot plots shown in
Fig. 1 demonstrate decrease in RTKN2 but an increase
in SELE and PI15 with a decrease in lung function. We
confirmed expression levels of these three genes in the
same set of LTRC samples by qRT-PCR (Fig. 2).
Given that analysis of expression changes as a function of
continuous decrease in lung function variables identified
large number of additional genes, we use the overlap be-
tween transcripts associated with a decline in DLCO or
FVC in the continuous analysis (553 unique transcripts) to
identify canonical pathways and transcriptional net-
works that are likely to be important predictors of se-
verity of IIPs. Canonical Pathways Analysis of the 553
genes identified hepatic fibrosis and hepatic stellate cell
activation (P <1 × < 10−7), acute phase response signaling
(P <1 × 10 −5), and HIF-1α signaling (P <1 × 10−4) as the
most significantly enriched (Fig. 3a). A number of other
pathways were identified (P <0.001) including IL17a, DC
and NK crosstalk, LPS/IL-1 mediated inhibition of RXR
function, leukocyte extravasation signaling, atherosclerosis
signaling, and aryl hydrocarbon receptor signaling.
Protein-protein interactome analysis using the InnateDB
database of interactions suggests that more severe presen-
tation of IIPs is characterized by an increase in cell cycle
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Table 2 Differentially expressed genes (5 % FDR) in severe vs mild disease as characterized both by a decline in % predicted DLCO
and FVC
Transcript ID Gene symbol p-value




(Severe vs Mild FVC)
Severe/Mild Fold Change
(FVC)
7922229 SELE 9.4E-05 2.87 2.9E-05 2.80
7921821 ADAMTS4 5.0E-05 2.22 2.8E-06 2.41
8146957 PI15 1.9E-05 2.04 1.7E-06 2.16
8043981 IL1R2 0.00035 1.86 2.5E-05 2.00
7976496 SERPINA3 9.5E-06 1.81 3.3E-05 1.76
8088560 ADAMTS9 1.4E-05 1.84 8.5E-05 1.75
8162276 NFIL3 0.00011 1.59 6.9E-06 1.63
7974851 HIF1A 6.8E-07 1.52 2.7E-07 1.57
8145122 SLC39A14 0.00012 1.51 1.9E-05 1.51
8113220 ELL2 8.2E-06 1.52 2.6E-05 1.51
8106743 VCAN 8.3E-05 1.48 0.00014 1.49
7921344 ELL2 1.6E-05 1.56 3.0E-05 1.49
7902227 GADD45A 2.6E-05 1.33 6.4E-08 1.48
8059376 SERPINE2 0.00031 1.57 0.00013 1.45
8043909 NPAS2 5.2E-05 1.56 0.00067 1.45
7897449 SPSB1 0.00011 1.36 4.3E-06 1.44
8044391 MERTK 0.00015 1.46 1.5E-05 1.43
8168749 SRPX2 1.9E-06 1.57 3.0E-05 1.43
8156043 PSAT1 0.00017 1.40 9.0E-06 1.43
8115814 SH3PXD2B 3.0E-05 1.47 3.0E-05 1.42
8106098 MAP1B 3.4E-05 1.48 0.00019 1.42
8157216 UGCG 3.8E-05 1.39 5.3E-06 1.41
8099685 LGI2 0.00032 1.45 0.00018 1.40
8007931 ITGB3 4.4E-05 1.37 5.2E-05 1.40
7986446 ALDH1A3 3.1E-05 1.49 0.0020 1.37
8105040 OSMR 0.00012 1.33 3.00E-05 1.35
8043995 IL1R1 3.4E-05 1.34 3.8E-05 1.35
7922610 ABL2 0.00034 1.39 3.8E-05 1.33
7915787 PIK3R3 2.9E-05 1.26 4.9E-05 1.33
8006123 CPD 0.00017 1.24 3.2E-05 1.27
8066939 B4GALT5 0.00026 1.25 3.2E-05 1.27
8133155 TPST1 0.00021 1.32 1.1E-05 1.25
8041168 SNORD53 0.00019 1.30 0.0018 1.25
8102482 SEC24D 1.0E-05 1.31 5.5E-05 1.24
8041149 WDR43 0.00010 1.29 0.00079 1.24
7985934 SEMA4B 0.00012 1.21 8.8E-05 1.23
8076515 ARFGAP3 0.00013 1.26 0.00035 1.21
8117128 E2F3 3.5E-06 1.27 0.00022 1.20
7966839 VSIG10 0.00021 −1.17 0.0026 −1.15
8109086 ADRB2 0.00015 −1.24 0.0013 −1.17
8035201 CPAMD8 5.5E-05 −1.30 0.0010 −1.22
8041206 LBH 0.00036 −1.33 0.0015 −1.26
7940530 C11orf9 3.2E-05 −1.24 0.0019 −1.27
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progression and apoptosis (genes centered around
MYC), increased hypoxia (genes centered around HIF-
1α) and dampened innate immune response (genes
centered around TNF-α) (Fig. 3b). Network analysis in
Ingenuity Pathway Analysis identified seven high
scoring networks (score >25; Additional file 1: Figure
S2) that largely recapitulate findings from InnateDB
database.
Validation of gene expression changes in an independent
cohort
To test the generalizability of our findings, we examined ex-
pression of the candidate genes with the strongest associa-
tions with DLCO and FVC in an independent cohort of
IIPs. Additional file 1: Table S6 provides characteristics of
the replication (National Jewish Health or NJH) cohort. We
primarily focused this analysis on the most pronounced
transcriptional changes, 4 genes with >2 fold change from
the categorical analysis of both FVC and DLCO (RTKN2,
PI15, ADAMTS4, and SELE; Table 2). We used the same
ANOVA models as in the derivation cohort, incorporating
lung function variable, IIP subtype, and smoking, on these
4 genes to assess whether there are significant differences
in expression between mild and severe disease, as defined
by percent predicted DLCO (22 mild and 17 severe) or
FVC (36 mild and 23 severe). The results of this analysis
(Table 3) demonstrate that extent of transcriptional changes
associated with lung function are dampened in this cohort
compared to the LTRC cohort. However, all genes have
p <0.05 for association with either FVC or DLCO. We
also performed an analysis to validate 58 genes from
Table 2 in the replication cohort in the same manner
as previous analysis. 44/58 (76 %) genes have nominal
p <0.05 in at least one of the analyses (Additional file
1: Table S7). We also considered lack of RB-ILD sam-
ples in the replication cohort as a counfounder of our
validation analysis. This subtype of IIPs is character-
ized by better lung function than IPF and iNSIP; pres-
ence of RB-ILD cases with better lung function creates
a wider range of values for FVC and DLCO in the
LTRC cohort and may potentially allow for identifica-
tion of more associations despite controlling for IIP
subtype in the model. 49/58 (85 %) genes identified as
significant in the categorical analysis of FVC and DLCO
(Table 2) remain significant after removal of RB-ILD sam-
ples from the analysis. Similarly, of the 533 genes identi-
fied in common to DLCO and FVC when considered as
continuous variables, 401 genes (75 %) remain significant
in the analysis without RB-ILD. Therefore, RB-ILD sam-
ples do not significantly influence the results of our ana-
lysis beyond loss of power with fewer samples.
Localization of gene expression changes
To partially address the issue of cell specificity of gene
expression profiles identified in whole lung tissue, we per-
formed immunohistochemistry to localize expression of
rhotekin 2, one of the genes with most prominent expres-
sion change associated with diseases progression and
severity, in normal and IIP lung. In histologically normal
lung tissue, rhotekin 2 is expressed in airway/bronchial
epithelia, alveolar epithelia, alveolar macrophages, and
submucosal glands (Additional file 1: Figure S3). We next
examined different histopathological features (airways,
honeycomb cysts and alveolar cysts) in lung tissue of IPF
subjects with more compared to less severe disease. While
we did not observe consistent differences across all
Table 2 Differentially expressed genes (5 % FDR) in severe vs mild disease as characterized both by a decline in % predicted DLCO
and FVC (Continued)
8149885 ADRA1A 1.7E-05 −1.33 4.1E-05 −1.27
8082465 CCDC48 9.8E-05 −1.28 8.1E-06 −1.28
8038117 DBP 0.00019 −1.35 0.00016 −1.31
8057677 SLC40A1 0.00038 −1.41 0.0023 −1.32
7968650 C13orf36 7.1E-06 −1.38 0.00019 −1.34
8089467 ZBED2 3.5E-05 −1.45 0.00021 −1.45
8171248 KAL1 5.3E-05 −1.67 0.00077 −1.50
8155734 FAM189A2 2.0E-05 −1.56 4.0E-05 −1.54
8156569 MIR23B 0.00024 −1.71 3.0E-06 −1.66
8179967 AGER 6.22E-05 −1.81 0.0023 −1.74
8125341 AGER 7.5E-05 −1.42 0.0026 −1.77
8178771 AGER 7.1E-05 −1.67 0.0025 −1.78
8109383 GRIA1 4.9E-06 −1.86 3.4E-05 −1.81
8171427 FIGF 0.00028 −2.07 0.0011 −1.90
7933855 RTKN2 0.00020 −2.57 0.0016 −2.34
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subjects we examined, we observed a trend of lower ex-
pression of rhotekin 2 in IPF airways (Fig. 4a), honeycomb
cysts (Fig. 4b), and alveolar cystic areas (Fig. 4c) of individ-
uals with more severe disease. Based on our data, reduced
mRNA levels of rhotekin 2 in severe IPF are most likely a
combination of reduced expression in specific cells and
loss of healthy airway epithelia that are replaced by honey-
comb cysts [16]. Localization of rhotekin 2 in iNSIP lung
tissue also demonstrated a decrease in expression in more
severe disease (Additional file 1: Figure S4). These findings
corroborate the findings of reduced rhotekin 2 expression
at the mRNA level in more severe IIPs.
Discussion
Results of our investigation of global gene expression
changes in lungs of patients with IIPs demonstrate that,
at the molecular level, there are more commonalities
than differences among different subtypes of IIPs. On
the other hand, the extent of disease, as characterized by
lower measures of FVC and DLCO, is associated with
marked changes in expression of novel and established
genes and pathways involved in IIPs.
Our findings that lung tissue from IPF, iNSIP, RB-ILD,
and uncharacterized fibrosis share many common ex-
pression patterns supports the concept that, despite dif-
ferences in clinical presentation, these diseases may be
related etiologically and pathogenically. Three publica-
tions [17–19] indicate that IPF/UIP and iNSIP, presumed
distinct clinical-pathologic processes, may be related
etiologically and pathogenically. Two of these studies
[17, 19] have used transcriptional profiles of affected
lung tissue to create IIP molecular signatures, and their
findings suggest that dissimilar histological patterns may
be related biologically.
In addition to some differences in expression among
different IIP subtypes, we identified more pronounced
Fig. 1 Categorical analysis of changes in gene expression based on lung disease severity categorized by % predicted DLCO (top) or % predicted FVC
(bottom) for novel IIP candidate genes rhotekin 2 (RTKN2 - left), selectin E (SELE - middle), and peptidase inhibitor 15 (PI15 – right). Mild, moderate,
and severe are defined as percent predicted DLCO (mild ≥65 %, moderate <65 % and >35 %, and severe ≤35 %), or FVC (mild ≥75 %, moderate <75 %
and >40 %, and severe ≤40 %). p values for severe vs mild groups are shown in Table 2
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changes in gene expression associated with more ad-
vanced disease. This conclusion is supported by previous
reports [20, 21]. Selman et al. identified 437 differentially
expressed genes in rapid compared to slow progressors, in-
cluding overexpression of genes involved in morphogenesis,
oxidative stress, migration/proliferation, and genes from fi-
broblasts/smooth muscle cells [20]. Our group also demon-
strated differential expression (p <0.05 and >5 fold change)
of 191 transcripts in individuals with progressive IPF (based
on changes in DLCO and FVC over 12 months) compared
to slow progressors [21]. While only less than 10 % of the
genes in Table 2 (AGER, C11orf9, NFIL3, PSAT1, RTKN2,
and SERPINE2) were identified by these earlier studies,
additional overlap was observed when we considered gene
families (for example GADD45A in the present study and
GADD45B in our earlier publication), suggesting that the
present study was successful at confirming published obser-
vations but also identifying novel gene transcripts. Two po-
tential explanations for limited overlap are the fact that
technologies and genome annotations have changed (our
earlier study used the Serial analysis of gene expression
[SAGE] as opposed to microarrays) and sample size (our
current study has considerably larger sample size than pre-
vious publications).
Among the gene transcripts most strongly associated
with disease severity are rhotekin 2 (RTKN2), selecting E
(SELE), and peptidase inhibitor 15 (PI15). Rhotekin 2 is a
member of a family of proteins containing a Rho-binding
domain that are target peptides for the Rho-GTPases and
are important in lymphocyte development and function
[22]; however rhotekin 2 is ubiquitously expressed [23].
Genetic variants in rhotekin 2 have been associated with
rheumatoid arthritis (RA) and activation of the NF-κB
pathway in Japanese [24]. These known roles for rhotekin
2, the observation of decreased expression of rhotekin 2 in
more severe disease, both in our earlier publication [21]
and in the current study, and localization of expression to
the lung epithelium in the current study, point to this
gene as a candidate that warrants further functional inves-
tigation in IIPs. Selectin E is a member of the selectin fam-
ily of cell adhesion molecules and plays a central role in
adhesion of leukocytes to the endothelium [25]. Its expres-
sion inhibits bleomycin-induced lung fibrosis [15] but the
soluble form of the protein product is increased in serum
of patients with pulmonary fibrosis [26]. Finally, PI15 is a
trypsin inhibitor that is developmentally regulated in the
lung mesenchyme [27] but otherwise is not well character-
ized; its role in development is consistent with recapitula-
tion of developmental pathways in lung injury that is a
hallmark of IIPs [28].
One of the strengths of the present study is the use of
two independent cohorts of IIP for derivation and valid-
ation. However, we were only able to validate the most pro-
nounced transcriptional changes identified in the derivation
cohort. One possible explanation for this is that overall the
NJH cohort has milder disease, an observation we have pre-
viously made [29]. We also considered the possibility that
lack of RB-ILD cases in the replication cohort contributed
to limited validation but ruled this out by showing that ex-
clusion of RB-ILD cases from the derivation cohort did not
substantially influence the results. A notable weaknesses of
the present study in that, analogous to earlier publications,
we have used whole lung tissue with the mixture of cells.
Immunohistochemistry analysis of rhotekin 2, one of the
genes with strongest correlation with disease severity in our
study, demonstrates that reduced expression may be a
Fig. 2 qRT-PCR validation of microarray data. Fold changes relative to control lungs for rhotekin 2 (black bars), selecting E (white bars) and PI15
(gray bars) in all IIPs and mild and severe disease based on either FVC or DLCO. Error bars represent standard deviations
Steele et al. BMC Genomics  (2015) 16:869 Page 7 of 12
combination of reduced expression in specific cells and loss
of healthy airway epithelia that are replaced by honeycomb
cysts. Further future studies will be needed to determine
which of the genes identified by our analysis are differen-
tially regulated in specific cell populations. Another weak-
ness of our study is cross-sectional design in which we
identify gene expression changes associated with a decline
in lung function across a cohort of different individuals. A
study of longitudinal design with measurements of gene ex-
pression and lung function over time in same individuals
will be needed to validate these findings. However, the find-
ing that rhotekin 2 expression was associated with more
rapid disease progression in our earlier study [21] supports
Fig. 3 553 differentially expressed genes common to FVC and DLCO by continuous analysis were evaluated by (a) canonical pathways and (b)
protein-protein interactome analysis. Pathways and their associated –log P value, as determined by the Fisher Exact Test in Ingenuity Pathway
Analysis, are shown as the blue bars. The ratio of the number of genes mapping to these pathways relative to the total number of genes in the
pathway is plotted as orange squares. The interactome was created using NetworkAnalyst [33] and the InnateDB PPI dataset by first importing all
553 genes and then reducing the network to zero-order interactome. The nodes are colored based on their correlation of expression and lung
function variables (green are negative and red are positive correlations). The sizes of nodes are proportional to their betweenness centrality values
Table 3 Validation of gene expression changes from the LTRC
IIP cohort in an independent cohort of IIPs (NJH cohort)
DLCO categorical FVC categorical
Gene symbol p-value Severe/mild fold p-value Severe/mild fold
ADAMTS4 0.001531 1.70 0.337822 1.12
PI15 0.046174 1.33 0.181961 1.27
RTKN2 0.252356 −1.27 0.045309 −2.32
SELE 0.000903 2.01 0.425210 −1.06
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Fig. 4 (See legend on next page.)
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the notion that genes identified in our study have direct
relevance to disease progression.
Conclusions
In summary, we identified commonalities and differences
in gene among different subtypes of IIP. Disease progres-
sion, as characterized by lower measures of FVC and
DLCO, results in marked changes in expression of novel
and established genes and pathways involved in IIP. These
genes and pathways represent strong candidates for bio-
marker studies and potential therapeutic targets for IIP
severity.
Methods
Subjects and tissue samples
All human tissue was collected with appropriate ethical
review for the protection of human subjects. Written
informed consent was obtained for all subjects’ participa-
tion in research by the Lung Tissue Research Consortium
and National Jewish Health ILD Research Program. The
current study only used de-identified information and was
determined to be non-human subject research by both
National Jewish Health and Colorado Multiple Institution
IRBs. ATS/ERS guidelines were followed for diagnosis of
IIP subtypes. The LTRC IIP cohort was used to derive gene
expression signatures. NJH IIP cohort was used to validate
gene expression signatures. The control tissue cohort
was split to provide control lung expression profiles
for both derivation and validation stages.
Lung tissue specimens from lower (n = 121), upper
(n = 31), and middle/lingula (n = 15) lobes from sub-
jects with IIP (119 IPF, 17 iNSIP, 13 uncharacterized fi-
brosis, 11 RB-ILD, 4 DIP, and 3 COP) were obtained
from the LTRC. The LTRC is a resource created by the
NHLBI to provide human lung tissues and DNA to
qualified investigators for use in research. The pro-
gram enrolls donor subjects who are anticipating lung
surgery, collects blood and extensive phenotypic data
from the prospective donors, and then processes their
surgical waste tissues for research use. Most donor sub-
jects have fibrotic interstitial lung disease or COPD. Clin-
ical data include clinical and pathological diagnoses, chest
CT images, pulmonary function tests (spirometry, DLCO,
and ABG), exposure (including cigarette smoking history)
and symptom questionnaires (including Borg dyspnea
scale), and family history of lung disease.
The NJH ILD cohort consists of 131 patients with
biopsy-proven IIP (111 IPF/UIP, 12 iNSIP, and 8
uncharacterized fibrosis) that were clinically evaluated
by investigators at National Jewish Health. All subjects in
this cohort have undergone a standardized evaluation de-
signed to provide a specific diagnosis. The evaluation in-
cluded a standardized history focused on the presence of
current or previous systemic disease; medications; tobacco
and recreational drug use; familial lung disease; avoca-
tional, occupational, environmental, and accidental expo-
sures. Additional testing includes serologic evaluation for
evidence of systemic disease, chest radiography, pulmonary
physiology (including lung volumes by body plethysmogra-
phy, spirometry before and after inhaled bronchodilator,
and diffusing capacity), pressure volume curves, and
gas exchange with exercise (formal six-minute walk
testing and/or cardiopulmonary exercise testing). Video
assisted thorascopic (VAT) or open surgical lung biopsy
was performed as clinically indicated. The diagnosis of
IIP was established using the criteria defined in the
ATS/ERS consensus statement [1, 2].
Control, non-diseased lung tissue from lower (n = 86),
and middle (n = 4) lobes was obtained from International
Institute for Advancement of Medicine, formerly Tissue
Transformation Technologies (Ediston, NJ). All individ-
uals had suffered brain death and were evaluated for
organ transplantation before research consent. Informed
consent was obtained at the time of transplant evaluation.
All specimens failed regional lung selection criteria for
transplantation. Subjects had to demonstrate no evidence
of active infection or chest radiographic abnormalities,
mechanical ventilation <48 h, PaO2/FiO2 ratio >200, and
no past medical history of underlying lung disease or sys-
temic disease that involves the lungs (e.g., rheumatoid
arthritis). Lung samples were procured within 34 h after
brain death (mean, 16.2 h; range, 4.5–33.25 h). The con-
trol cohort was divided to proportionally provide the same
percentage controls to LTRC and NJH IIP cohorts; 50
controls were used with the LTRC cohort and 40 with the
NJH cohort.
Microarray data generation
Total RNA including small RNA species was isolated
from approximately 100 mg of snap-frozen lung tissue
using the mirVana kit (AB/Ambion, Austin TX). RNA
purity and concentration were determined by spectro-
photometry, and RNA integrity was determined using
(See figure on previous page.)
Fig. 4 Localization of rhotekin 2 expression in IPF lung of patients with mild (left panels) and severe (right panels) disease. Immunohistochemical
staining of airways (a), honeycomb cysts (b), and alveolar cysts (c) lung tissue reveals some decrease in expression of rhotekin 2 in airway epithelial
cells in patients with severe compared to mild disease accompanied by an increase in expression in hyperplastic alveolar type II cells in alveolar cysts.
Top panels represent rhotekin 2 stained sections and bottom panels are corresponding tissue sections incubated with non-immune serum (negative
primary antibody controls). Tissue sections were counterstained with hematoxylin. Images were taken at 10× and 40× (inset) magnifications
Steele et al. BMC Genomics  (2015) 16:869 Page 10 of 12
the Bioanalyzer (Agilent, Santa Clara, CA). mRNA micro-
array target labeling was conducted using 300 ng of total
RNA and the Message Amp II kit (AB/Ambion, Austin
TX), hybridized to the Human Gene 1.0 ST Array
(Affymetrix, Santa Clara, CA) and processed according
to the manufacturer’s instructions. All microarray data
met the quality control criteria established by the Tumor
Analysis Best Practices Working Group [30] and are
available in the Gene Expression Omnibus repository
as GSE31962.
Microarray data analysis
Expression data from 217 mRNA arrays (LTRC cohort;
167 IIPs and 50 controls) were analyzed using ANOVA
implemented in Partek (St Louis, MO). Intensity data were
imported, log2-transformed, and quantile normalized
using RMA [31], and expression levels were summarized
on a transcript level using the mean value of all probesets
mapping to a transcript. Non-expressed and invariant
transcripts were removed using a median variance filter,
corrected by a Benjamini-Hochberg false discovery rate
(FDR) of 0.10 [32], resulting in a final dataset of 11950
transcript measurements across 217 samples. Differential
expression of individual transcripts was identified using an
ANOVA (for categorical analysis) or ANCOVA (for con-
tinuous analysis) model incorporating lung function vari-
able (%predicted FVC or DLCO), the final clinical
diagnosis of each subject and smoking status. We included
age and smoking status in the model as there are signifi-
cant differences in these variables between IIP and control
groups. We considered the impact of several technical
variables including array batch, RNA preservative, RNA
quality (RIN) and anatomic location of the lung biopsy;
minimal expression changes were associated with these
variables and we therefore did not include them in the
final model. NJH cohort mRNA expression profiles
were collected and processed in the same manner as
the LTRC cohort data, with the exception of the final
filtering step; in this case, 11950 transcripts from the
LTRC dataset were retained in the dataset. Pathway
analysis was performed using the Ingenuity Pathway
Analysis (IPA) database and software (www.ingenuity.
com) and the Fisher Exact Test to determine significant
enrichments. We used the Network Analyst tool to gener-
ate the protein-protein interactome. NetworkAnalyst uses
a comprehensive high-quality protein-protein interaction
(PPI) database based on InnateDB [33]. The database con-
tains manually curated protein interaction data from pub-
lished literature as well as experimental data from several
PPI databases including IntAct, MINT, DIP, BIND, and
BioGRID. The database currently contains 14755 proteins
and 145955 interactions for human, and 5657 proteins and
14491 interactions for mouse.
Quantitative RT-PCR
Primers for mRNA expression were designed using Primer-
BLAST and are listed in Additional file 1: Table S8. RNA
was normalized to a concentration of 100 ng/μL and
reverse transcribed to cDNA using the Applied Biosys-
tems High Capacity cDNA Reverse Transcription Kit.
Each 20-μL PCR contained 15 ng cDNA, 0.5 μM final
concentration of forward and reverse primers and 1×
final concentration of the Power SYBR Green master
mix. Real-time PCR was performed on an Applied Bio-
systems Viia 7 instrument using the following profile:
50 °C for 2 min, 95 °C for 10 min, and 40 cycles of
95 °C for 15 s, and 60 °C for 1 min. Dissociation
curves were collected at the end of each run. ΔCT
values were calculated relative to GAPDH, and ΔΔCT
values were calculated by comparison among different
groups of samples.
Immunohistochemistry
Standard immunohistochemical staining protocols were
followed. Briefly, histological sections of normal and IPF
lung were deparaffinized, blocked with hydrogen perox-
ide, followed by antigen retrieval in citrate buffer, and
non-immune serum block. RTKN2 anti-rabbit antibody
(Sigma, St. Louis MO; product number HPA037946)
was added to histological sections at 1:200 final dilution
and incubated overnight. Secondary antibody staining
was performed with 3, 3′-diaminobenzidine (DAB) using
the ImmPRESS kit (Vector Laboratories, Burlingame
CA) and RTKN2 was visualized using the peroxidase
substrate (ImmPact DAB kit). The sections were coun-
terstained with hematoxylin. The primary antibody was
replaced by non-immune serum for negative control
slides.
Additional file
Additional file 1: Supplemental Figures and Tables. (PDF 2199 kb)
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